Nintedanib Clonmel

Nintedanib, the active ingredient in Nintedanib Clonmel, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in appropriately selected patients.

GNH USA supplies Nintedanib Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network complies with EU regulations and ensures product integrity through validated cold‑chain logistics where required.

Nintedanib is employed in fibrotic lung disorders and selected oncology settings, targeting pathways that drive fibroblast proliferation and tumor angiogenesis.

- Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilises respiratory status. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor angiogenesis and proliferation.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and clinical severity.

Common Side Effects: - Nausea - Diarrhoea - Vomiting - Decreased appetite - Abdominal pain - Weight loss

Serious or Rare Side Effects: - Elevated liver enzymes (ALT/AST) - Severe bleeding events - Cardiovascular complications (e.g., myocardial infarction) - Gastrointestinal perforation - Pulmonary embolism - Severe infections

Before initiating therapy, clinicians should assess organ function and potential risk factors.

- Liver monitoring: perform baseline and periodic liver function tests. - Cardiovascular assessment: evaluate history of heart disease or thromboembolic events. - Bleeding risk: use caution in patients receiving anticoagulants or antiplatelet agents. - Pregnancy: avoid use; safety in pregnancy and lactation is unknown. - Hepatic impairment: dose adjustment may be required in moderate to severe liver dysfunction. - Store at below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with several drug classes, necessitating careful review of concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). - Anticoagulants (e.g., warfarin) – increased bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel) – heightened hemorrhage. - P‑gp inhibitors (e.g., verapamil) – elevated plasma levels. - CYP2C8 inhibitors (e.g., gemfibrozil) – increased exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin) – reduced efficacy. - Moderate CYP2C8 inhibitors (e.g., trimethoprim). - Non‑steroidal anti‑inflammatory drugs – additive gastrointestinal toxicity. - Statins metabolised by CYP3A4 (e.g., simvastatin) – risk of myopathy. - Diuretics – monitor electrolytes and renal function.